Anti-inflammatory properties of genetically modified lactic acid bacteria

Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases: Bioactive Food in Chronic Disease States

Volumn , Issue , 2012, Pages 581-600

  del Carmen, S ^a   de Moreno de LeBlanc, A ^a   Miyoshi, A ^b   Azevedo, V ^b   Bermudez Humaran L G ^c   Langella, P ^c   LeBlanc, J G ^a  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85053415273     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-397156-2.00225-8     Document Type: Chapter

References (53)

1. Braat H., Rottiers P., Hommes D.W., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clinical Gastroenterology and Hepatology 2006, 4:754-759.
2. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009, 58:1152-1167.
3. Bruno-Barcena J.M., Andrus J.M., Libby S.L., Klaenhammer T.R., Hassan H.M. Expression of a heterologous manganese superoxide dismutase gene in intestinal lactobacilli provides protection against hydrogen peroxide toxicity. Applied and Environmental Microbiology 2004, 70:4702-4710.
4. Carroll I.M., Andrus J.M., Bruno-Barcena J.M., et al. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. American Journal of Physiology - Gastrointestinal and Liver Physiology 2007, 293:G729-G738.
5. Cong Y., Weaver C.T., Lazenby A., Elson C.O. Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. Journal of Immunology 2002, 169:6112-6119.
6. Chandran P., Satthaporn S., Robins A., Eremin O. Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (I). The Surgeon 2003, 1:63-75.
7. De Ruyter P.G., Kuipers O.P., De Vos W.M. Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Applied and Environmental Microbiology 1996, 62:3662.
8. Dieye Y., Oxaran V., Ledue-Clier F., et al. Functionality of sortase A in Lactococcus lactis. Applied and Environmental Microbiology 2010, 76:7332-7337.
9. FAO/WHO, 2010. Expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report, Cordoba, Argentina, pp. 1-4.
10. Favier C., Neut C., Mizon C., et al. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Digestive Diseases and Sciences 1997, 42:817-822.
11. Foligne B., Nutten S., Grangette C., et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World Journal of Gastroenterology 2007, 13:236-243.
12. Friedman G., George J.T. Treatment of refractory 'pouchitis' with prebiotic and probiotic therapy. Gastroenterology 2000, 118:A4167.
13. Frossard C.P., Steidler L., Eigenmann P.A. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. The Journal of Allergy and Clinical Immunology 2007, 119:952-959.
14. Gupta P., Andrew H., Kirschner B.S., Guandalini S. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. Journal of Pediatric Gastroenterology and Nutrition 2000, 31:453-457.
15. Han W., Mercenier A., Ait-Belgnaoui A., et al. Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflammatory Bowel Diseases 2006, 12:1044-1052.
16. Kappeler A., Mueller C. The role of activated cytotoxic T cells in inflammatory bowel disease. Histology and Histopathology 2000, 15:167-172.
17. Kolandaswamy A., George L., Sadasivam S. Heterologous expression of oxalate decarboxylase in Lactobacillus plantarum NC8. Current Microbiology 2009, 58:117-121.
18. Kruidenier L., van Meeteren M.E., Kuiper I., et al. Attenuated mild colonic inflammation and improved survival from severe DSS-colitis of transgenic Cu/Zn-SOD mice. Free Radical Biology & Medicine 2003, 34:753-765.
19. Kullisaar T., Zilmer M., Mikelsaar M. Two antioxidative lactobacilli strains as promising probiotics. International Journal of Food Microbiology 2002, 72:215-224.
20. LeBlanc J.G., de Moreno de LeBlanc A., Perdigón G., et al. Anti-inflammatory properties of lactic acid bacteria: current knowledge, applications and prospects. Anti-Infective Agents Medicinal Chemistry 2008, 7:148-154.
21. LeBlanc J.G., Sybesma W., Starrenburg M., et al. Supplementation with engineered Lactococcus lactis improves the folate status in deficient rats. Nutrition 2010, 26:835-841.
22. LeBlanc J.G., del Carmen S., Miyoshi A., et al. Use of superoxide dismutase and catalase expressing lactic acid bacteria to attenuate TNBS induced Crohn's disease in mice. Journal of Biotechnology 2011, 151(3):287-293.
23. Leon F., Smythies L.E., Smith P.D., Kelsall B.L. Involvement of dendritic cells in the pathogenesis of inflammatory bowel disease. Advances in Experimental Medicine and Biology 2006, 579:117-132.
24. Loos M., Remaut E., Rottiers P., De Creus A. Genetically engineered Lactococcus lactis secreting murine IL-10 modulates the functions of bone marrow-derived dendritic cells in the presence of LPS. Scandinavian Journal of Immunology 2009, 69:130-139.
25. Madsen K.L., Doyle J.S., Jewell L.D., Tavernini M.M., Fedorak R.N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999, 116:1107-1114.
26. Malin M., Suomalainen H., Saxelin M., Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Annals of Nutrition and Metabolism 1996, 40:137-145.
27. Marinho F.A., Pacifico L.G., Miyoshi A., et al. An intranasal administration of Lactococcus lactis strains expressing recombinant interleukin-10 modulates acute allergic airway inflammation in a murine model. Clinical and Experimental Allergy 2010, 40:1541-1551.
28. Mengheri E. Health, probiotics and inflammation. Journal of Clinical Gastroenterology 2008, 42:S177-S178.
29. Miyoshi A., Bermúdez-Humarán L.G., Azevedo M.S.P.D., Langella P., Azevedo V. Lactic acid bacteria as live vectors: heterologous protein production and delivery systems. Biotechnology of Lactic Acid Bacteria Novel Applications 2010, 161-176. Wiley-Blackwell, Ames, Iowa. F. Mozzi, R.R. Raya, G.M. Vignolo (Eds.).
30. Miyoshi A., Jamet E., Commissaire J., et al. A xylose inducible expression system for Lactococcus lactis. FEMS Microbiology Letters 2004, 239:205-212.
31. de Moreno de LeBlanc A., Chaves S., Perdigon G. Effect of yoghurt on the cytokine profile using a murine model of intestinal inflammation. European Journal of Inflammation 2009, 7:97-109.
32. de Moreno de LeBlanc A., LeBlanc J.G., Perdigon G., et al. Oral administration of a catalase-producing Lactococcus lactis can prevent a chemically induced colon cancer in mice. Journal of Medical Microbiology 2008, 57:100-105.
33. O'Mahony L., Feeney M., O'Halloran S., et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Alimentary Pharmacology and Therapeutics 2001, 15:1219-1225.
34. Pena J.A., Versalovic J. Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cellular Microbiology 2003, 5:277-285.
35. Reveneau N., Geoffroy M.-C., Locht C., Chagnaud P., Mercenier A. Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations. Vaccine 2002, 20:1769-1777.
36. Rochat T., Bermudez-Humaran L., Gratadoux J.J., et al. Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. Microbial Cell Factories 2007, 6:1-10.
37. Rochat T., Miyoshi A., Gratadoux J.J., et al. High-level resistance to oxidative stress in Lactococcus lactis conferred by Bacillus subtilis catalase KatE. Microbiology 2005, 151:3011-3018.
38. Roselli M., Finamore A., Nuccitelli S., et al. Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium Strains is associated with an expansion of gamma delta T and regulatory T cells of intestinal intraepithelial lymphocytes. Inflammatory Bowel Diseases 2009, 15:1526-1536.
39. Round J.L., Mazmanian S.K. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proceedings of the National Academy of Sciences USA 2010, 107:12204-12209.
40. Sanders J.W., Leenhouts K.J., Haandrikman A.J., Venema G., Kok J. Stress response in Lactococcus lactis: cloning, expression analysis, and mutation of the lactococcal superoxide dismutase gene. Journal of Bacteriology 1995, 177:5254-5260.
41. Schotte L., Steidler L., Vandekerckhove J., Remaut E. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme and Microbial Technology 2000, 27:761-765.
42. Schultz M., Veltkamp C., Dieleman L.A., et al. Lactobacillus plantarum 299v in the treatment and prevention of spontaneous colitis in Interleukin-10-deficient mice. Inflammatory Bowel Diseases 2002, 8:71-80.
43. Segui J., Gironella M., Sans M., et al. Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. Journal of Leukocyte Biology 2004, 76:537-544.
44. Steidler L., Hans W., Schotte L., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
45. Steidler L., Neirynck S., Huyghebaert N., et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nature Biotechnology 2003, 21:785-789.
46. Szatrowski T.P., Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Research 1991, 51:794-798.
47. Tournoy K.G., Kips J.C., Pauwels R.A. Endogenous interleukin-10 suppresses allergen-induced airway inflammation and nonspecific airway responsiveness. Clinical and Experimental Allergy 2000, 30:775-783.
48. Vandenbroucke K., Hans W., Van Huysse J., et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004, 127:502-513.
49. Venturi A., Gionchetti P., Rizzello F., et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics 1999, 13:1103-1108.
50. Videla S., Vilaseca J., Guarner F., et al. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994, 35:1090-1097.
51. Waeytens A., Ferdinande L., Neirynck S., et al. Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice. Inflammatory Bowel Diseases 2008, 14:471-479.
52. Watterlot L., Rochat T., Sokol H., et al. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. International Journal of Food Microbiology 2010, 144(1):35-41.
53. Wells J.M., Wilson P.W., Norton P.M., Gasson M.J., Le Page R.W.F. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Molecular Microbiology 1993, 8:1155-1162.